LATEST TWEETS - CURATED BY HASH FINANCE
@juliaskripkaser Thanks for sharing the microcap names.
Given $XFOR lack of data in WB and SCN, how confident are… https://t.co/FdGVucl9zC
@BiotekOie Something I should’ve mentioned in the thread - one pt discontinued 6 days after starting, total n=7.
3… https://t.co/NxtqC6GmPx
https://t.co/eH4tFgSPhN X4 Pharmaceuticals Inc The model computed that this stock s value has a negative short term… https://t.co/fLbRosigzN
4/ $XFOR continued ASH data:
75% wart burden for 300/400mg pts
Most important point note of the P3 trial - primar… https://t.co/hx1DcQMTj5
3/ $XFOR WHIM P3 data in 2022 but summary of recent WHIM Data at ASH 2020:
- Dose-dependent decreases in WBC, ANC,… https://t.co/4lip1Mbjzr
2/ $XFOR recently received RPD so PRV is likely worth the entire current valuation less cash.
Very strong leadersh… https://t.co/HpImj0F4St
A quick thread on $XFOR as initial data for Waldenstrom and SCN approaches:
Quick evaluation:
1. Market Cap - $13… https://t.co/fUTiqtW2Fp
Things I like this q:
$anvs - data by March. Tiny float, huge indication
$xfor - works in WM, huge market, data in… https://t.co/qkpLxmaMtS
